59.3 F
Laguna Hills
Tuesday, May 28, 2024
-Advertisement-

DAVID MOATAZEDI

 CEO, PRESIDENT EVOLUS INC.

WHY: Runs neurotoxin upstart, maker of Jeuveau, touted as a cheaper, more effective version of Allergan’s Botox. Held senior marketing roles with Allergan for more than a decade, including SVP of medical aesthetics, before joining Evolus in 2018.

RECENT: Secured $40M investment from South Korean pharmaceutical firm and partner Daewoong Pharmaceutical in July.

QUOTABLE: Jeuveau “exists to bring options and choice back to the market,” which hasn’t “seen a new market entrant in nearly a decade.”

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-